Evaluation of Immune Checkpoint Inhibitors in a Jurkat-Based Transcriptional Reporter System: A Cell-Based Reporter Platform for Evaluation of Immune Checkpoint Inhibitors.

Magdalena Bojko, Judith Leitner, Peter Steinberger

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Magdalena BojkoDepartment of Biomedical Chemistry, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland. magdalena.bojko@phdstud.ug.edu.pl.

Judith LeitnerDivision of Immune Receptors and T Cell Activation, Institute of Immunology, Medical University of Vienna, Vienna, Austria.

Peter SteinbergerDivision of Immune Receptors and T Cell Activation, Institute of Immunology, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Humanity has been facing cancer since the beginning of its existence, and the number of new cancer cases grows each year. Immunotherapies based on immune checkpoint inhibition have been intensively developed over the last decade and focus on the blockade of the co-inhibitory molecule complexes such as CTLA-4 with its ligands CD80 and CD86, PD-1 with PD-L1 and PD-L2, and many more. The investigation and development of new immune checkpoints inhibitors is necessary for better cancer treatment. One way of inhibitor evaluation is to assess them in cell-based assays. In this protocol, we focus on describing the cell-based reporter platform for PD-1/PD-L1 inhibitors assessment, which is based on measuring the expression of eGFP under the transcription factor NF-κB, responsible for transcriptional program required for T-cell activation and differentiation.

Indexed as

Genes, ReporterImmune Checkpoint InhibitorsB7-H1 AntigenGreen Fluorescent ProteinsHumansJurkat CellsLymphocyte ActivationNF-kappa BProgrammed Cell Death 1 ReceptorT-LymphocytesTranscription, GeneticB7-H1 AntigenCD274 protein, humanGreen Fluorescent ProteinsImmune Checkpoint InhibitorsNF-kappa BProgrammed Cell Death 1 ReceptorCell-based reporter platformImmune checkpoint inhibitorsInhibitors evaluationPD-1PD-L1

Identifiers

PMID41028259

DOI10.1016/j.tranon.2024.101892

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.